Viewing Study NCT00043706


Ignite Creation Date: 2025-12-26 @ 1:19 PM
Ignite Modification Date: 2025-12-29 @ 5:26 PM
Study NCT ID: NCT00043706
Status: COMPLETED
Last Update Posted: 2015-03-05
First Post: 2002-08-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Sponsor: Genzyme, a Sanofi Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module